Anti-VEGF Cancer Therapy in Nephrology Practice

Expanded clinical experience with the antivascular endothelial growth factor (VEGF) agents has come with increasing recognition of their renal adverse effects. Although renal histology is rarely sought in antiangiogenic-treated cancer patients, kidney damage related to anti-VEGF is now established....

Descripción completa

Detalles Bibliográficos
Autor principal: Izzedine, Hassan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158308/
https://www.ncbi.nlm.nih.gov/pubmed/25210627
http://dx.doi.org/10.1155/2014/143426
_version_ 1782334028283641856
author Izzedine, Hassan
author_facet Izzedine, Hassan
author_sort Izzedine, Hassan
collection PubMed
description Expanded clinical experience with the antivascular endothelial growth factor (VEGF) agents has come with increasing recognition of their renal adverse effects. Although renal histology is rarely sought in antiangiogenic-treated cancer patients, kidney damage related to anti-VEGF is now established. Its manifestations include hypertension, proteinuria, and mainly glomerular thrombotic microangiopathy. Then, in nephrology practice, should we continue to perform kidney biopsy, and what should be done with the anti-VEGF agents in case of renal toxicity?
format Online
Article
Text
id pubmed-4158308
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-41583082014-09-10 Anti-VEGF Cancer Therapy in Nephrology Practice Izzedine, Hassan Int J Nephrol Review Article Expanded clinical experience with the antivascular endothelial growth factor (VEGF) agents has come with increasing recognition of their renal adverse effects. Although renal histology is rarely sought in antiangiogenic-treated cancer patients, kidney damage related to anti-VEGF is now established. Its manifestations include hypertension, proteinuria, and mainly glomerular thrombotic microangiopathy. Then, in nephrology practice, should we continue to perform kidney biopsy, and what should be done with the anti-VEGF agents in case of renal toxicity? Hindawi Publishing Corporation 2014 2014-08-24 /pmc/articles/PMC4158308/ /pubmed/25210627 http://dx.doi.org/10.1155/2014/143426 Text en Copyright © 2014 Hassan Izzedine. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Izzedine, Hassan
Anti-VEGF Cancer Therapy in Nephrology Practice
title Anti-VEGF Cancer Therapy in Nephrology Practice
title_full Anti-VEGF Cancer Therapy in Nephrology Practice
title_fullStr Anti-VEGF Cancer Therapy in Nephrology Practice
title_full_unstemmed Anti-VEGF Cancer Therapy in Nephrology Practice
title_short Anti-VEGF Cancer Therapy in Nephrology Practice
title_sort anti-vegf cancer therapy in nephrology practice
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158308/
https://www.ncbi.nlm.nih.gov/pubmed/25210627
http://dx.doi.org/10.1155/2014/143426
work_keys_str_mv AT izzedinehassan antivegfcancertherapyinnephrologypractice

Ejemplares similares